Evidence map›Paper›PMID 42786151›Full record

ArticleNature communications2026

Therapeutic modulation of the vitreoretinal fibrosis microenvironment in female mice using engineered macrophage-derived extracellular vesicles.

Yingjie Wang, Fuxiao Luan, Jiawei Zhao, Peilin Guo, Shuang Wang, Jinghui Wang, Dongfang Wang, Jing Hou, Xiaofeng Hu, Li Chen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yingjie WangDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China.
Fuxiao LuanDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China.
Jiawei ZhaoDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China.ORCID http://orcid.org/0000-0003-3343-4676
Peilin GuoState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, PR China.
Shuang WangState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, PR China.ORCID http://orcid.org/0000-0002-9189-602X
Jinghui WangDepartment of Gastroenterology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.ORCID http://orcid.org/0000-0002-5888-5708
Dongfang WangBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, PR China.ORCID http://orcid.org/0000-0003-1368-028X
Jing HouDepartment of Ophthalmology, Peking University People's Hospital, Beijing, PR China.
Xiaofeng HuDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China.
Li ChenDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China.
Xusheng CaoBeijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.
Guanghui MaState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, PR China. ghma@ipe.ac.cn.ORCID http://orcid.org/0000-0001-9154-5556
Yong TaoDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China. taoyong@mail.ccmu.edu.cn.ORCID http://orcid.org/0000-0003-1443-2667
Ying TianDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China. tianying@mail.ccmu.edu.cn.ORCID http://orcid.org/0000-0003-3239-6567
Wei WeiState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, PR China. weiwei@ipe.ac.cn.ORCID http://orcid.org/0000-0002-6244-3187

Funding

National Natural Science Foundation of China (National Science Foundation of China) T2225021
6 · The paper itself

Abstract

Vitreoretinal fibrosis, a hallmark of proliferative vitreoretinopathy (PVR) triggered by retinal detachment or ocular trauma, necessitates surgery. Through data mining of the vitreoretinal fibrosis microenvironment in PVR patients and mice, showing elevated transforming growth factor β1 (TGFβ1) and M2 macrophage enrichment, we designed and engineered extracellular vesicles that conferred anti-fibrotic efficacy against PVR. These M1 macrophage-derived vesicles (M1evs) were conjugated with anti-TGFβ1 antibodies (aT) via MMP-cleavable linkers (aT-cl-M1ev, termed ACE). Upon intravitreal injection in female PVR model mice, ACE selectively accumulates in lesions, where released antibodies neutralize TGFβ1 and M1evs inhibit M2 macrophage polarization, modulating the microenvironment to diminish vitreoretinal fibrosis. Further incorporating anti-platelet-derived growth factor receptor antibodies yields aTP-cl-M1ev (ACE

Indexed as

Cellular MicroenvironmentExtracellular VesiclesMacrophagesVitreoretinopathy, ProliferativeAnimalsDisease Models, AnimalFemaleFibrosisHumansIntravitreal InjectionsMiceMice, Inbred C57BLRetinaRetinal DetachmentTransforming Growth Factor beta1Vitreous BodyTransforming Growth Factor beta1

Identifiers

PMID42786151
PMCPMC13612821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.